GT Biopharma appoints new director, amends equity facility to raise up to $20M

GT Biopharma, Inc.

Andrew Ritter resigned from board effective June 9, 2025.
David C. Mun-Gavin appointed as director and chair of compensation committee on June 10, 2025.
Amendment to Common Shares Purchase Agreement increases Bristol Capital's beneficial ownership limit to 9.99%.
Equity facility remains at $20M; change gives more flexibility for future stock sales.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David C. Mun-Gavin

Non-employee Director and Chair of the Compensation Committee

GTBP · GT Biopharma, Inc.

Effective: 2025-06-10
Filed: June 11, 2025, 7:59 PM ET

On June 10, 2025, the Board appointed David C. Mun-Gavin as a non-employee director of the Board.

Departed

Andrew Ritter

Member of the Board of Directors

GTBP · GT Biopharma, Inc.

Effective: 2025-06-09
Filed: June 11, 2025, 7:59 PM ET

On June 9, 2025, Andrew Ritter resigned as a member of the board of directors (the “Board”) of the Company and all committees thereof.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David C. Mun-Gavin was appointed as Non-employee Director and Chair of the Compensation Committee at GT Biopharma, Inc..

Action: appointed
Role: Non-employee Director and Chair of the Compensation Committee

Exact text from the filing

On June 10, 2025, the Board appointed David C. Mun-Gavin as a non-employee director of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Ritter resigned as Member of the Board of Directors at GT Biopharma, Inc..

Action: resigned
Role: Member of the Board of Directors

Exact text from the filing

On June 9, 2025, Andrew Ritter resigned as a member of the board of directors (the “Board”) of the Company and all committees thereof.

View on SEC.gov

GT Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-014700

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.